Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Maria Chianese(University of Trieste), Barbara Ruaro(University of Trieste), Michael Hughes(Dana-Farber/Harvard Cancer Center), Lucrezia Mondini(University of Trieste), Marco Confalonieri(University of Trieste), Nicolò Reccardini(University of Trieste), Paola Confalonieri(University of Trieste), Mariangela Barbieri(University of Trieste), Liliana Trotta(University of Trieste), Francesco Salton(University of Trieste), Pietro Geri(University of Trieste), Luca Ruggero(University of Trieste), Gianluca Screm(University of Trieste), Marco Mari(University of Trieste), Selene Lerda(University of Milan)
Cited by 86
Related Papers
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
|Journal of Clinical Oncology|2014|777
miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation
|ERJ Open Research|2019|59
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
|Cell Death and Disease|2013|57
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
|British Journal of Cancer|2010|49